Antibiotic Resistance Market By Resistant Bacteria Type (Pseudomonas Aeruginosa, Clostridioides difficile (C. difficile), Carbapenem-resistant Enterobacteriaceae (CRE), Streptococcus pneumoniae (S. pneumoniae), Acinetobacter, Vancomycin-resistant Enterococci (VRE), Mycobacterium Tuberculosis (TB), Neisseria gonorrhoeae (N. gonorrhoeae), and Others); By Disease Indication (Complicated Urinary Tract Infections (cUTI), Complicated Intra-Abdominal Infections (cIAI), Community-Acquired Bacterial Pneumonia (CABP), Acute Skin and Skin Structure Infections (ABSSSI), Multidrug-Resistant (MDR) & Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB & XDR-TB), Sepsis, Clostridium Difficile (C. difficile) Infections, and Others); By Drug Class (Antimycobacterials, Fluoroquinolones, Oxazolidinones, Tetracyclines, Penicillins, Antifolates, Combination Treatment, and Others); By Route of Administration (Oral, Topical, Intramuscular, and Intravenous (IV)); By End Use (Home Care, Healthcare Facilities, and Others); By Region (By Region (U.S., Canada, Mexico, Rest of North America, The UK, France, Germany, Italy, Spain, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, the Netherlands, Luxembourg), Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029